Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 24, 2026, 9:16 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 193–216 of 5,025 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Radiation Clear all
Terminated Not applicable Interventional Results available

Y90 Radiation Segmentectomy vs SBRT for HCC

NCT04235660
View directory record Official record
Conditions
Hepatocellular Carcinoma (HCC)
Interventions
Yttrium-90 Radiation Segmentectomy, Stereotactic Body Radiation Therapy
Radiation
Lead sponsor
Indiana University
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Oct 25, 2023 · Synced Oct 24, 2026, 9:16 AM EDT
Completed No phase listed Observational

Self-Reported Exercise Behavior and Short-Term Patient Outcomes in Women Undergoing Radiation Treatment for Operable Breast Cancer

NCT02050620
View directory record Official record
Conditions
Breast Cancer
Interventions
Not listed
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Dec 3, 2015 · Synced Oct 24, 2026, 9:16 AM EDT
Completed Phase 2Phase 3 Interventional Results available

FACBC Outcomes for Post Prostatectomy

NCT01666808
View directory record Official record
Conditions
Prostate Cancer
Interventions
FACBC, Radiation therapy
Drug · Radiation
Lead sponsor
Emory University
Other
Eligibility
18 Years to 95 Years · Male only
Enrollment
165 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2022
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Aug 2, 2023 · Synced Oct 24, 2026, 9:16 AM EDT
Completed Phase 2 Interventional Results available

Hypofractionated Boost Before Chemoradiation for Patients With Stage II-III Non-small Cell Lung Cancer Unsuitable for Surgery

NCT02262325
View directory record Official record
Conditions
Recurrent Non-small Cell Lung Cancer, Stage IIA Non-small Cell Lung Cancer, Stage IIB Non-small Cell Lung Cancer, Stage IIIA Non-small Cell Lung Cancer, Stage IIIB Non-small Cell Lung Cancer
Interventions
hypofractionated radiation therapy, cisplatin, etoposide, 3-dimensional conformal radiation therapy, laboratory biomarker analysis
Radiation · Drug · Other
Lead sponsor
Ohio State University Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2024
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 12, 2025 · Synced Oct 24, 2026, 9:16 AM EDT
Completed Phase 1 Interventional

Study Evaluating CMP-001 in Combination With Atezolizumab in Participants With Non-Small Cell Lung Cancer

NCT03438318
View directory record Official record
Conditions
Non Small Cell Lung Cancer
Interventions
CMP-001, Atezolizumab, Radiation Therapy
Drug · Radiation
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
5
States / cities
Gilbert, Arizona • Duarte, California • Aurora, Colorado + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 3, 2022 · Synced Oct 24, 2026, 9:16 AM EDT
Terminated No phase listed Observational

Assessment of 3D Transperineal Ultrasound Imaging w/ Matrix Array Transducers in Prostate Radiotherapy

NCT02432820
View directory record Official record
Conditions
Prostate Cancer
Interventions
Not listed
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older · Male only
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Jun 11, 2021 · Synced Oct 24, 2026, 9:16 AM EDT
Completed Phase 3 Interventional Results available

Paclitaxel, Cisplatin, and Radiation Therapy With or Without Cetuximab in Treating Patients With Locally Advanced Esophageal Cancer

NCT00655876
View directory record Official record
Conditions
Esophageal Cancer
Interventions
cetuximab, cisplatin, paclitaxel, radiation therapy
Drug · Radiation
Lead sponsor
Radiation Therapy Oncology Group
Network
Eligibility
18 Years to 74 Years
Enrollment
344 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2022
U.S. locations
173
States / cities
Tucson, Arizona • Auburn, California • Cameron Park, California + 140 more
Source: ClinicalTrials.gov public record
Updated Jun 14, 2022 · Synced Oct 24, 2026, 9:16 AM EDT
Completed Phase 1 Interventional Results available

Risk-Guided Cardioprotection With Carvedilol in Breast Cancer Patients Treated With Doxorubicin and/or Trastuzumab

NCT04023110
View directory record Official record
Conditions
Cardiotoxicity, Risk Factor, Cardiovascular, Toxicity Due to Chemotherapy, Breast Cancer, Cardiomyopathies, Heart Failure
Interventions
Carvedilol
Drug
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years and older · Female only
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 9, 2025 · Synced Oct 24, 2026, 9:16 AM EDT
Completed Not applicable Interventional Results available

Study of Personalized Sterile Humidification Device for Mucositis in Head and Neck Cancer Patients

NCT01930435
View directory record Official record
Conditions
Head and Neck Cancer
Interventions
Sterile Humidification Device
Device
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Aug 10, 2017 · Synced Oct 24, 2026, 9:16 AM EDT
Completed Phase 3 Interventional Results available

Hypofractionated Image-Guided Radiation Therapy (IGRT) in Patients With Stage II-III Non-Small Cell Lung Cancer

NCT01459497
View directory record Official record
Conditions
Non-small Cell Lung Cancer
Interventions
Radiation Therapy, Conventional radiation
Radiation
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 99 Years
Enrollment
103 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2023
U.S. locations
7
States / cities
Austin, Texas • Dallas, Texas • Houston, Texas + 4 more
Source: ClinicalTrials.gov public record
Updated Jan 17, 2024 · Synced Oct 24, 2026, 9:16 AM EDT
Completed Not applicable Interventional Results available

Hypofractionated Radiation Therapy to Improve Immunotherapy Response in Non-Small Cell Lung Cancer

NCT03035890
View directory record Official record
Conditions
Non Small Cell Lung Cancer Metastatic
Interventions
Radiation, Immuno-Therapeutic Agent
Radiation · Drug
Lead sponsor
West Virginia University
Other
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
1
States / cities
Morgantown, West Virginia
Source: ClinicalTrials.gov public record
Updated Apr 1, 2025 · Synced Oct 24, 2026, 9:16 AM EDT
Withdrawn Phase 2 Interventional

Neoadjuvant Bevacizumab and Carboplatin Followed by Concurrent Bevacizumab, Carboplatin and Radiotherapy in the Primary Treatment of Cervix Cancer

NCT00600210
View directory record Official record
Conditions
Cervical Cancer
Interventions
Bevacizumab, Carboplatin, Radiation Therapy
Drug · Radiation
Lead sponsor
Leo W. Jenkins Cancer Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Greenville, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 23, 2017 · Synced Oct 24, 2026, 9:16 AM EDT
Completed Phase 1 Interventional

Nab-Paclitaxel, Capecitabine, and Radiation Therapy Following Induction Chemotherapy in Treating Patients With Locally Advanced Pancreatic Cancer

NCT02394535
View directory record Official record
Conditions
Borderline Resectable Pancreatic Adenocarcinoma, Locally Advanced Pancreatic Adenocarcinoma, Pancreatic Adenocarcinoma, Stage II Pancreatic Cancer AJCC v6 and v7, Stage IIA Pancreatic Cancer AJCC v6 and v7, Stage IIB Pancreatic Cancer AJCC v6 and v7, Stage III Pancreatic Cancer AJCC v6 and v7
Interventions
Capecitabine, Laboratory Biomarker Analysis, Nab-paclitaxel, Questionnaire Administration, Radiation Therapy
Drug · Other · Radiation
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
19 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2022
U.S. locations
5
States / cities
Houston, Texas • League City, Texas • Sugar Land, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 2, 2022 · Synced Oct 24, 2026, 9:16 AM EDT
Active, not recruiting Phase 2 Interventional Results available

Phase II Study of Short Course FOLFOX Chemotherapy With Either Nivolumab or Nivolumab + Radiation in the First Line Treatment of Metastatic or Unresectable Gastroesophageal Cancers (BMS Protocol CA209-76L)

NCT04021108
View directory record Official record
Conditions
Gastroesophageal Adenocarcinoma
Interventions
Nivolumab 240 MG
Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
5
States / cities
Tampa, Florida • St Louis, Missouri • Omaha, Nebraska + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 21, 2026 · Synced Oct 24, 2026, 9:16 AM EDT
Terminated No phase listed Observational

QOL & Functional Outcomes After Combined Modality Tx for Anal CA: Comparison of Conventional vs IMRT

NCT00568425
View directory record Official record
Conditions
Anal Cancer
Interventions
Not listed
Lead sponsor
Stanford University
Other
Eligibility
30 Years to 70 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Jun 29, 2020 · Synced Oct 24, 2026, 9:16 AM EDT
Completed Phase 2 Interventional

Radiolabeled Monoclonal Antibody, Cyclophosphamide, and Total Body Irradiation Followed By Donor Stem Cell Transplantation in Treating Patients With Advanced Acute Myeloid Leukemia

NCT00003868
View directory record Official record
Conditions
Leukemia
Interventions
cyclophosphamide, methotrexate, allogeneic bone marrow transplantation, peripheral blood stem cell transplantation, iodine I 131 monoclonal antibody BC8, radiation therapy
Drug · Procedure · Radiation
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
2 Years to 55 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2005
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Aug 24, 2010 · Synced Oct 24, 2026, 9:16 AM EDT
Terminated Phase 3 Interventional

Combination Chemotherapy, Surgery, and Radiation Therapy With or Without Dexrazoxane and Trastuzumab in Treating Women With Stage III or Stage IV Breast Cancer

NCT00016276
View directory record Official record
Conditions
Cardiac Toxicity, Inflammatory Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IV Breast Cancer
Interventions
dexrazoxane hydrochloride, doxorubicin hydrochloride, cyclophosphamide, paclitaxel, trastuzumab, therapeutic conventional surgery, radiation therapy, tamoxifen citrate, laboratory biomarker analysis
Drug · Biological · Procedure + 2 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Female only
Enrollment
396 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2001
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jan 16, 2013 · Synced Oct 24, 2026, 9:16 AM EDT
Enrolling by invitation No phase listed Observational

Assessing the System for High-Intensity Evaluation During Radiotherapy During Changes in Response to COVID-19

NCT04357574
View directory record Official record
Conditions
COVID-19, Cancer
Interventions
Telehealth
Other
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 6, 2026 · Synced Oct 24, 2026, 9:16 AM EDT
Recruiting Not applicable Interventional

Daily Adaptive Radiation Therapy Using an Individualized Approach for Prostate Cancer

NCT05804318
View directory record Official record
Conditions
Prostate Cancer
Interventions
Daily adaptive SBRT with urethral sparing
Device
Lead sponsor
Varian, a Siemens Healthineers Company
Industry
Eligibility
18 Years and older · Male only
Enrollment
132 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2031
U.S. locations
5
States / cities
Duarte, California • Irvine, California • Boston, Massachusetts + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 9, 2026 · Synced Oct 24, 2026, 9:16 AM EDT
Recruiting Phase 2 Interventional

PSMA-High: EBRT/ PSMA617/ ADT vs. EBRT/ ADT

NCT07550517
View directory record Official record
Conditions
High-Risk Localized Prostate Cancer
Interventions
EBRT + 6 mo ADT + 177Lu-PSMA-617, EBRT + 24 mo ADT
Drug · Radiation
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older · Male only
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2033
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 22, 2026 · Synced Oct 24, 2026, 9:16 AM EDT
Recruiting Phase 1 Interventional

Hyaluronic Acid-based Gel Spacers in Gynecologic Malignancies

NCT07292818
View directory record Official record
Conditions
Cervix Cancer
Interventions
Barrigel gel spacer
Device
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 1, 2026 · Synced Oct 24, 2026, 9:16 AM EDT
Recruiting Phase 1Phase 2 Interventional

Low-Dose Radiotherapy for Alzheimer's Disease

NCT07693140
View directory record Official record
Conditions
Alzheimer Dementia, Dementia, Alzheimer Dementia (AD), Alzheimer, Alzheimer s Disease
Interventions
Low Dose Radiation Therapy
Radiation
Lead sponsor
Evan Thomas
Other
Eligibility
50 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Winter Park, Florida
Source: ClinicalTrials.gov public record
Updated Jul 9, 2026 · Synced Oct 24, 2026, 9:16 AM EDT
Completed Phase 2 Interventional

Radiation Therapy Plus Paclitaxel in Treating Patients With Stage IIB or Stage III Breast Cancer

NCT00003050
View directory record Official record
Conditions
Breast Cancer
Interventions
cyclophosphamide, doxorubicin hydrochloride, paclitaxel, tamoxifen citrate, surgical procedure, radiation therapy
Drug · Procedure · Radiation
Lead sponsor
University of Southern California
Other
Eligibility
18 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2000
U.S. locations
2
States / cities
Los Angeles, California • Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated May 22, 2014 · Synced Oct 24, 2026, 9:16 AM EDT
Active, not recruiting Phase 2 Interventional

Evaluating the Safety and Efficacy of a Novel Accelerated Partial Breast Irradiation Regimen

NCT05591547
View directory record Official record
Conditions
Breast Cancer
Interventions
IMRT/VMAT-Based Accelerated Partial Breast Irradiation
Radiation
Lead sponsor
Sanford Health
Other
Eligibility
50 Years and older · Female only
Enrollment
91 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
2
States / cities
Worthington, Minnesota • Sioux Falls, South Dakota
Source: ClinicalTrials.gov public record
Updated May 6, 2026 · Synced Oct 24, 2026, 9:16 AM EDT